These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Psychiatric symptoms in patients with Shiga toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome. Kleimann A; Toto S; Eberlein CK; Kielstein JT; Bleich S; Frieling H; Sieberer M PLoS One; 2014; 9(7):e101839. PubMed ID: 25007072 [TBL] [Abstract][Full Text] [Related]
6. Outbreak of hemolytic uremic syndrome with unusually severe clinical presentation caused by Shiga toxin-producing Escherichia coli O26:H11 in France. Minary K; Tanne C; Kwon T; Faudeux C; Clave S; Langevin L; Pietrement C; Enoch C; Parmentier C; Mariani-Kurkdjian P; Weill FX; Jones G; Djouadi N; Morin D; Fila M Arch Pediatr; 2022 Aug; 29(6):448-452. PubMed ID: 35662540 [TBL] [Abstract][Full Text] [Related]
7. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults. Derad I; Obermann B; Katalinic A; Eisemann N; Knobloch JK; Sayk F; Wellhöner P; Lehnert H; Solbach W; Süfke S; Steinhoff J; Nitschke M Nephrol Dial Transplant; 2016 Jan; 31(1):95-103. PubMed ID: 26180049 [TBL] [Abstract][Full Text] [Related]
8. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R; Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903 [TBL] [Abstract][Full Text] [Related]
9. Associations of age and sex with the clinical outcome and incubation period of Shiga toxin-producing Escherichia coli O104:H4 infections, 2011. Werber D; King LA; Müller L; Follin P; Buchholz U; Bernard H; Rosner B; Ethelberg S; de Valk H; Höhle M Am J Epidemiol; 2013 Sep; 178(6):984-92. PubMed ID: 23935124 [TBL] [Abstract][Full Text] [Related]
10. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. Frank C; Werber D; Cramer JP; Askar M; Faber M; an der Heiden M; Bernard H; Fruth A; Prager R; Spode A; Wadl M; Zoufaly A; Jordan S; Kemper MJ; Follin P; Müller L; King LA; Rosner B; Buchholz U; Stark K; Krause G; N Engl J Med; 2011 Nov; 365(19):1771-80. PubMed ID: 21696328 [TBL] [Abstract][Full Text] [Related]
11. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Greinacher A; Friesecke S; Abel P; Dressel A; Stracke S; Fiene M; Ernst F; Selleng K; Weissenborn K; Schmidt BM; Schiffer M; Felix SB; Lerch MM; Kielstein JT; Mayerle J Lancet; 2011 Sep; 378(9797):1166-73. PubMed ID: 21890192 [TBL] [Abstract][Full Text] [Related]
12. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008. Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224 [TBL] [Abstract][Full Text] [Related]
13. Psychological outcome, fatigue, and quality of life after infection with shiga toxin-producing Escherichia coli O104. Löwe B; Andresen V; Fraedrich K; Gappmayer K; Wegscheider K; Treszl A; Riegel B; Rose M; Lohse AW; Broicher W Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1848-55. PubMed ID: 24632347 [TBL] [Abstract][Full Text] [Related]
14. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Braune SA; Wichmann D; von Heinz MC; Nierhaus A; Becker H; Meyer TN; Meyer GP; Müller-Schulz M; Fricke J; de Weerth A; Hoepker WW; Fiehler J; Magnus T; Gerloff C; Panzer U; Stahl RA; Wegscheider K; Kluge S Crit Care Med; 2013 Jul; 41(7):1702-10. PubMed ID: 23660733 [TBL] [Abstract][Full Text] [Related]
15. Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Bauer A; Loos S; Wehrmann C; Horstmann D; Donnerstag F; Lemke J; Hillebrand G; Löbel U; Pape L; Haffner D; Bindt C; Ahlenstiel T; Melk A; Lehnhardt A; Kemper MJ; Oh J; Hartmann H Pediatr Nephrol; 2014 Sep; 29(9):1607-15. PubMed ID: 24664191 [TBL] [Abstract][Full Text] [Related]
16. Molecular epidemiology of a household outbreak of Shiga-toxin-producing Escherichia coli in Poland due to secondary transmission of STEC O104:H4 from Germany. Januszkiewicz A; Szych J; Rastawicki W; Wołkowicz T; Chróst A; Leszczyńska B; Kuźma E; Roszkowska-Blaim M; Gierczyński R J Med Microbiol; 2012 Apr; 61(Pt 4):552-558. PubMed ID: 22135021 [TBL] [Abstract][Full Text] [Related]
17. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. Nitschke M; Sayk F; Härtel C; Roseland RT; Hauswaldt S; Steinhoff J; Fellermann K; Derad I; Wellhöner P; Büning J; Tiemer B; Katalinic A; Rupp J; Lehnert H; Solbach W; Knobloch JK JAMA; 2012 Mar; 307(10):1046-52. PubMed ID: 22416100 [TBL] [Abstract][Full Text] [Related]